WO2004014298A2 - Composition and method for lowering cholesterol - Google Patents

Composition and method for lowering cholesterol Download PDF

Info

Publication number
WO2004014298A2
WO2004014298A2 PCT/US2003/023885 US0323885W WO2004014298A2 WO 2004014298 A2 WO2004014298 A2 WO 2004014298A2 US 0323885 W US0323885 W US 0323885W WO 2004014298 A2 WO2004014298 A2 WO 2004014298A2
Authority
WO
WIPO (PCT)
Prior art keywords
leaves
drymifolia
composition
cholesterol
persea americana
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/023885
Other languages
French (fr)
Other versions
WO2004014298A3 (en
WO2004014298B1 (en
Inventor
Ernesto A. Brovelli
Julio Andres Vallejos
Haeri Roh-Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Access Business Group International LLC
Original Assignee
Access Business Group International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access Business Group International LLC filed Critical Access Business Group International LLC
Priority to JP2004527681A priority Critical patent/JP2005534714A/en
Priority to AU2003257051A priority patent/AU2003257051A1/en
Publication of WO2004014298A2 publication Critical patent/WO2004014298A2/en
Publication of WO2004014298A3 publication Critical patent/WO2004014298A3/en
Publication of WO2004014298B1 publication Critical patent/WO2004014298B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to compositions and methods for lowering cholesterol. More particularly, the present invention relates compositions and methods having avocado leaf of the species Persea americana var. drymifolia (hereinafter referred to as "drymifolia”) for use in lowering cholesterol levels in humans.
  • drymifolia avocado leaf of the species Persea americana var. drymifolia
  • Cholesterol is a soft, waxy substance found among the lipids in the bloodstream and in cells of the human body. Although cholesterol serves needed bodily functions, too high a level of cholesterol in the blood may be detrimental to a person's health because it increases the risk of cardiovascular disease.
  • High cholesterol generally means that a person's total blood cholesterol level is more than 240 mg/dl or that a person's low density lipoprotein level is more than 160 mg/dl (see, Cleeman, James I., Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel JJI), JAMA 285(19): 2486-2497 (2001)). Approximately 41.3 million Americans have total blood cholesterol levels of 240mg/dL or higher (see, American Heart Association, Biostatistical Fact Sheet, www.americanheart.org (2002)).
  • LDL low-density lipoproteins
  • HDL high density proteins
  • statins There are several classes of available lipid-regulating pharmacological interventions called statins.
  • statins One common statin is Lipitor®. Although these agents have been proven safe in clinical trials, like any drug, they carry the risk for side-effects. Most notable of the side-effects is myopathy, which becomes evident as muscle pains and weakness.
  • the present invention is a composition containing avocado leaves from the variety drymifolia for reducing cholesterol levels.
  • the leaves are dehydrated and milled for consumption as a tea.
  • the leaves of drymifolia showed a comparable cholesterol lowering effect to Lipitor® and a much greater cholesterol lowering effect than the fruit and the leaves of Persea nubigena var. guatamalensis cv. Nabal and Persea nubigena var. guatamalensis cv. Haas, which are avocados commonly grown in North America.
  • FIG. 1 is a graph displaying dose specific responses of Hepatocyte G2 cells to hand-crushed and milled leaves of drymifolia in comparison to Lipitor® in cholesterol release.
  • FIG. 2 is a graph displaying dose specific responses of Hepatocyte G2 cells to milled leaves of drymifolia in comparison to milled leaves of Persea nubigena var. guatamalensis cv. Nabal and milled leaves of Persea nubigena var. guatamalensis cv. Haas in cholesterol release.
  • FIG. 3 is a graph displaying dose specific responses of Hepatocyte G2 cells to milled leaves of drymifolia in comparison to the fruit of Persea nubigena var. guatamalensis cv. Haas in cholesterol release. Best Mode for Carrying Out the Invention
  • the present invention comprises avocado leaves from the variety Persea americana var. drymifolia ("drymifolia"). This variety is available in Northern Argentina. The particular substance(s) in the leaves that causes cholesterol lowering is not yet understood. However, it is a commonly understood principle in the herbal industry that active ingredients in fresh plants/herbs generally decompose or diminish in effectiveness as the plant/herb dies or decays. Thus, to preserve the cholesterol reducing capacity of the drymifolia leaves for shipment from Argentina to the United States, the fresh drymifolia leaves are preferably air dried at average room temperatures of about 60°F to about 80°F. This temperature range is maintained until the leaves are prepared for consumption.
  • this preconditioning step maintains the efficacy of the drymifolia leaves in lowering cholesterol.
  • the leaves are preferably hand-crushed.
  • the hand-crushed leaves showed better cholesterol lowering activity than the fruit and leaves of Persea nubigena var. guatamalensis cv. Nabal ("Nabal") and the leaves of Persea nubigena var. guatamalensis cv. Haas ("Haas").
  • dehydrated leaves are milled using a 2 mm screen to mill the leaves to an average particle size of about 28 microns. Even more preferably, the leaves may be milled twice using a 1 mm screen to provide an average particle size of about 9 microns.
  • the dehydrated leaves may be milled using a 1 mm screen, providing an average particle size of about 11 microns. Milling can be performed by a GlenMills hammer mill bench top unit (Mot. KM 80-60, Culatti Typ MFC). Milled drymifolia leaves showed greater cholesterol reduction than hand-crushed drymifolia leaves. It is contemplated that the milled and dehydrated leaves can be used in the form of tea, capsules, tablets, creams, gels, liquids, and foods. However, for exemplary purposes, preparation and consumption in the form of a tea is described.
  • the tea is prepared as a 1% extract by preparing 10 mg of hand-crushed drymifolia leaves or milled drymifolia leaves per 1 ml of water. In one embodiment, 100 mg of drymifolia leaves are placed in 10 ml of water to form a tea. The tea is boiled for about 1 minute to about 10 minutes. More preferably, the tea is boiled for about 3 minutes to about 7 minutes and, most preferably, for about 5 minutes. The water can be boiling after or upon immersing the drymifolia leaves in the water. It will be appreciated by those of ordinary skill in the art that the boiling times will vary depending upon the volume of the tea. Drymifolia Comparison Studies
  • DMEM Dulbecco's Modified Eagle Medium
  • DMEM Dulbecco's Modified Eagle Medium
  • the final concentration is about 0.2 mg/ml to about 0.4 mg/ml drymifolia leaves and, most preferably, about 0.4 mg/ml drymifolia leaves.
  • the culture media provides all necessary nutrients for cell maintenance including cholesterol synthesis.
  • Amounts of secreted cholesterol and cholesteryl ester were measured from acetate fed hepatocyte culture media using a fluorescent indicator, Amplex Red. As shown in FIG.l, it is apparent that the effect of milled drymifolia leaves is comparable to that of Lipitor®. The results also show that milled drymifolia leaves with an average particle size of about 11 microns had a more favorable result than that of hand-crushed drymifolia leaves when water extracts are made from each.
  • the response of hepatocytes also indicated little or no toxicity associated with the doses treated when cell survival post treatment was assessed via MTT (3-[4,5-dimethylthiazol-2yl]-2,5 -diphenyltetrazolium bromide, Sigma, St. Louis, MO) reduction assay.
  • FIG. 2 shows the effect of the milled drymifolia leaves to milled leaves of Haas and Nabal.
  • FIG. 2 shows that drymifolia leaves have a more favorable effect in decreasing cholesterol synthesis/secretion than that of Haas or Nabal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition comprising Persea american var. drymifolia for lowering cholesterol levels.

Description

COMPOSITION AND METHOD FOR LOWERING CHOLESTEROL
Technical Field
[001] The present invention relates to compositions and methods for lowering cholesterol. More particularly, the present invention relates compositions and methods having avocado leaf of the species Persea americana var. drymifolia (hereinafter referred to as "drymifolia") for use in lowering cholesterol levels in humans.
Background Art [002] Cholesterol is a soft, waxy substance found among the lipids in the bloodstream and in cells of the human body. Although cholesterol serves needed bodily functions, too high a level of cholesterol in the blood may be detrimental to a person's health because it increases the risk of cardiovascular disease. High cholesterol generally means that a person's total blood cholesterol level is more than 240 mg/dl or that a person's low density lipoprotein level is more than 160 mg/dl (see, Cleeman, James I., Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel JJI), JAMA 285(19): 2486-2497 (2001)). Approximately 41.3 million Americans have total blood cholesterol levels of 240mg/dL or higher (see, American Heart Association, Biostatistical Fact Sheet, www.americanheart.org (2002)). When blood cholesterol reaches these high levels, it can build up on artery walls because cholesterol does not dissolve in the blood. Rather, cholesterol has to be transported to and from the cells by special carriers called low-density lipoproteins (LDL) and high density proteins (HDL). HDL carries cholesterol away from your arteries and is, thus, considered "good cholesterol." Too much LDL cholesterol can clog the arteries to your heart and is, thus, considered "bad cholesterol." This condition, called atherosclerosis, increases the risk of blood clots, heart attack, and stroke.
[003] Accordingly, there is considerable amount of interest in regulating cholesterol level in the body. There are several classes of available lipid-regulating pharmacological interventions called statins. One common statin is Lipitor®. Although these agents have been proven safe in clinical trials, like any drug, they carry the risk for side-effects. Most notable of the side-effects is myopathy, which becomes evident as muscle pains and weakness. Furthermore, it is important to minimize the potential for adverse reactions or drug interactions when a patient is undergoing statin therapy (see, Davidson, Michael H., Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions, J Cardiovasc Pharmacol Therapeut, 6(3): 219-229 (2001)). In its Adult Treatment Panel, the National Cholesterol Education Program recommends the use of plant derived substances in the adjuvant therapies for dyslipidemias (see Cleeman, supra). Accordingly, natural alternatives with effective and safe cholesterol reduction are desired.
Disclosure of the Invention [004] The present invention is a composition containing avocado leaves from the variety drymifolia for reducing cholesterol levels. In one embodiment the leaves are dehydrated and milled for consumption as a tea. Surprisingly, the leaves of drymifolia showed a comparable cholesterol lowering effect to Lipitor® and a much greater cholesterol lowering effect than the fruit and the leaves of Persea nubigena var. guatamalensis cv. Nabal and Persea nubigena var. guatamalensis cv. Haas, which are avocados commonly grown in North America.
[005] These and other aspects and advantages of the present invention will be better understood by reference to the drawings and the detailed description of the preferred embodiment. It is noted that, unless otherwise stated, all percentages given in this specification and the appended claims refer to percentages by weight.
Brief Description of The Drawings
[006] FIG. 1 is a graph displaying dose specific responses of Hepatocyte G2 cells to hand-crushed and milled leaves of drymifolia in comparison to Lipitor® in cholesterol release.
[007] FIG. 2 is a graph displaying dose specific responses of Hepatocyte G2 cells to milled leaves of drymifolia in comparison to milled leaves of Persea nubigena var. guatamalensis cv. Nabal and milled leaves of Persea nubigena var. guatamalensis cv. Haas in cholesterol release. [008] FIG. 3 is a graph displaying dose specific responses of Hepatocyte G2 cells to milled leaves of drymifolia in comparison to the fruit of Persea nubigena var. guatamalensis cv. Haas in cholesterol release. Best Mode for Carrying Out the Invention
[009] The present invention comprises avocado leaves from the variety Persea americana var. drymifolia ("drymifolia"). This variety is available in Northern Argentina. The particular substance(s) in the leaves that causes cholesterol lowering is not yet understood. However, it is a commonly understood principle in the herbal industry that active ingredients in fresh plants/herbs generally decompose or diminish in effectiveness as the plant/herb dies or decays. Thus, to preserve the cholesterol reducing capacity of the drymifolia leaves for shipment from Argentina to the United States, the fresh drymifolia leaves are preferably air dried at average room temperatures of about 60°F to about 80°F. This temperature range is maintained until the leaves are prepared for consumption.
Surprisingly, this preconditioning step maintains the efficacy of the drymifolia leaves in lowering cholesterol.
[010] Once dehydrated, the leaves are preferably hand-crushed. The hand-crushed leaves showed better cholesterol lowering activity than the fruit and leaves of Persea nubigena var. guatamalensis cv. Nabal ("Nabal") and the leaves of Persea nubigena var. guatamalensis cv. Haas ("Haas"). More preferably, dehydrated leaves are milled using a 2 mm screen to mill the leaves to an average particle size of about 28 microns. Even more preferably, the leaves may be milled twice using a 1 mm screen to provide an average particle size of about 9 microns. Most preferably, the dehydrated leaves may be milled using a 1 mm screen, providing an average particle size of about 11 microns. Milling can be performed by a GlenMills hammer mill bench top unit (Mot. KM 80-60, Culatti Typ MFC). Milled drymifolia leaves showed greater cholesterol reduction than hand-crushed drymifolia leaves. It is contemplated that the milled and dehydrated leaves can be used in the form of tea, capsules, tablets, creams, gels, liquids, and foods. However, for exemplary purposes, preparation and consumption in the form of a tea is described.
[011] The tea is prepared as a 1% extract by preparing 10 mg of hand-crushed drymifolia leaves or milled drymifolia leaves per 1 ml of water. In one embodiment, 100 mg of drymifolia leaves are placed in 10 ml of water to form a tea. The tea is boiled for about 1 minute to about 10 minutes. More preferably, the tea is boiled for about 3 minutes to about 7 minutes and, most preferably, for about 5 minutes. The water can be boiling after or upon immersing the drymifolia leaves in the water. It will be appreciated by those of ordinary skill in the art that the boiling times will vary depending upon the volume of the tea. Drymifolia Comparison Studies
[012] To test the efficacy of the drymifolia tea containing milled drymifolia leaves having an average particle size of about 11 microns, comparison studies were performed with tea containing hand-crushed drymifolia leaves, Lipitor®, Haas fruit, and milled leaves of Haas and Nabal having an average particle size of about 11 microns. Lipitor® is prepared in methanol/buffer to solubilize atorvastatin, the active ingredient in Lipitor® (40 mg active/600 mg tablet). All test materials were applied to serum culture medium at varying doses.
[013] Tea containing drymifolia leaves having an average particle size of about 11 microns was added to Dulbecco's Modified Eagle Medium (DMEM, Catalogue # 11965, In Vitrogen Corporation, 1600 Faraday Avenue, P.O. Box 6482, Carlsbad, California 92008) to a final concentration of about O.lmg/ml to about 0.5 mg/ml drymifolia leaves via serial dilution (or 0.01% to 0.05% drymifolia leaves). More preferably, the final concentration is about 0.2 mg/ml to about 0.4 mg/ml drymifolia leaves and, most preferably, about 0.4 mg/ml drymifolia leaves. The culture media provides all necessary nutrients for cell maintenance including cholesterol synthesis.
Components of Culture Medium Molarity
Figure imgf000005_0001
INORGANIC SALTS:
Calcium Chloride (CaC12) (anhyd.) 1.80
Ferric Nitrate (Fe(NO3)3-9H2O) 0.000248
Potassium Chloride (KC1) 5.30
Magnesium Sulfate (MgSO4) 0.813
Sodium Chloride (NaCl) 110.34
Sodium Bicarbonate (NaHCO3) 44.10
Sodium Phosphate (NaH2PO4-H2O) 0.906
OTHER COMPONENTS:
D-Glucose 25.00
Phenol red 0.0346
AMLNO ACIDS:
L-Arginine-HCl 0.398
L-Cystine 2HC1 0.200
L-Glutamine 4.00
Glycine 0.399
L-Histidine HC1-H2O 0.20
L-Isoleucine 0.802
L-Leucine 0.802
L-Lysine-HCl 0.798
L-Methionine 0.201 L-Phenylalanine 0.400
L-Serine 0.400
L-Threonine 0.078
L-Tryptophan 0.078
L-Tyrosine 2Na 2H20 0.398
L-Valine 0.803 VITAMINS:
D-Ca pantothenate 0.0083
Choline Chloride 0.0285
Folic Acid 0.00906 i-Inositol 0.04
Niacinamide 0.0328
Pyridoxine HC1 0.0196
Riboflavin 0.00106
Thiamine HCl 0.0118
[014] Amounts of secreted cholesterol and cholesteryl ester were measured from acetate fed hepatocyte culture media using a fluorescent indicator, Amplex Red. As shown in FIG.l, it is apparent that the effect of milled drymifolia leaves is comparable to that of Lipitor®. The results also show that milled drymifolia leaves with an average particle size of about 11 microns had a more favorable result than that of hand-crushed drymifolia leaves when water extracts are made from each. The response of hepatocytes also indicated little or no toxicity associated with the doses treated when cell survival post treatment was assessed via MTT (3-[4,5-dimethylthiazol-2yl]-2,5 -diphenyltetrazolium bromide, Sigma, St. Louis, MO) reduction assay.
[015] FIG. 2 shows the effect of the milled drymifolia leaves to milled leaves of Haas and Nabal. FIG. 2 shows that drymifolia leaves have a more favorable effect in decreasing cholesterol synthesis/secretion than that of Haas or Nabal.
[016] As shown in FIG. 3, when the cholesterol inhibitory effect of Haas fruit is assessed in comparison to that of the milled drymifolia leaves, the milled leaves again exerted much more favorable response than the fruit.
[017] While the above describes what are presently believed to be the preferred embodiments of the invention, those skilled in the art will realize that changes and modifications may be made thereto without departing from the spirit of the invention. It is intended to claim all such changes and modifications that fall within the true scope of the invention.

Claims

What is Claimed:
1. A composition comprising an effective amount of Persea americana var. drymifolia leaves for lowering cholesterol levels.
2. The composition of claim 1 wherein said composition is in the form of a tea.
3. The composition of claim 1 wherein said composition is a dietary supplement.
4. The composition of claim 1 wherein said composition lowers total blood cholesterol levels by about 10% to about 40%.
5. The composition of claim 1 wherein said Persea americana var. drymifolia leaves have an average particle size of about 11 microns.
6. The composition of claim 1 wherein said Persea americana var. drymifolia leaves are present in the amount of about 0.01% to about 0.05%
7. The composition of claim 1 wherein said Persea americana var. drymifolia leaves are present in the amount of about 0.04%.
8. The tea of claim 7 wherein said Persea americana var. drymifolia leaves have an average particle size of about 9 microns to about 28 microns.
9. A tea comprising about 0.1 mg/ml to about 0.5 mg/ml of Persea americana var. drymifolia leaves.
10. A method of lowering cholesterol levels comprising administering to a subject an effective amount of Persea americana var. drymifolia leaves.
11. The method of claim 10 wherein said Persea americana var. drymifolia leaves lower total blood cholesterol levels by about 10% to about 35%.
12. The method of claim 10 wherein said effective amount of Persea americana var. drymifolia leaves is about 0.01% to about 0.05%
13. A method of preparing a cholesterol lowering composition comprising the steps of: (a) dehydrating leaves of Persea americana var. drymifolia;
(b) milling the leaves to an average particle size of about 9 microns to about 28 microns; and
(c) heating about 0.1 mg/ml to about 0.5 mg/ml of the milled leaves in boiling water.
PCT/US2003/023885 2002-07-31 2003-07-31 Composition and method for lowering cholesterol Ceased WO2004014298A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2004527681A JP2005534714A (en) 2002-07-31 2003-07-31 Compositions and methods for lowering cholesterol
AU2003257051A AU2003257051A1 (en) 2002-07-31 2003-07-31 Composition and method for lowering cholesterol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/209,021 2002-07-31
US10/209,021 US6793946B2 (en) 2002-07-31 2002-07-31 Composition and method for lowering cholesterol

Publications (3)

Publication Number Publication Date
WO2004014298A2 true WO2004014298A2 (en) 2004-02-19
WO2004014298A3 WO2004014298A3 (en) 2004-07-01
WO2004014298B1 WO2004014298B1 (en) 2004-08-26

Family

ID=31186940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/023885 Ceased WO2004014298A2 (en) 2002-07-31 2003-07-31 Composition and method for lowering cholesterol

Country Status (7)

Country Link
US (1) US6793946B2 (en)
JP (1) JP2005534714A (en)
KR (1) KR20050026084A (en)
CN (1) CN1681523A (en)
AU (1) AU2003257051A1 (en)
TW (1) TW200404560A (en)
WO (1) WO2004014298A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501004A (en) * 2004-05-28 2008-01-17 ラボラトワール エクスパンシアンス Use of furan alkyls to produce drugs for the treatment of obesity and cosmetic treatment of overweight
JP2008501003A (en) * 2004-05-28 2008-01-17 ラボラトワール エクスパンシアンス Use of furanalkyl to manufacture antidiabetic drugs
WO2017063150A1 (en) * 2015-10-14 2017-04-20 高雄医学大学 Application of avocado extract, avocadenol b, and (2r,4r)-1,2,4-trihydroxy heptadec-16-yne, and health food comprising avocado extract

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100592A1 (en) * 2004-04-13 2005-10-27 Rush University Medical Center A pharmacologic method of lowering cholesterol production
TWI605822B (en) * 2015-04-09 2017-11-21 高雄醫學大學 Uses of an avocado extract, avocadenol b, and (2r,4r)-1,2,4-trihydroxyheptadec-16-yne, and health food containing the avocado extract
US11399652B2 (en) 2016-12-29 2022-08-02 Koninklijke Philips N.V. Method and device for providing a coffee beverage with reduced terpene content
CN112425668A (en) * 2020-09-28 2021-03-02 广西南亚热带农业科学研究所 Processing method of avocado leaf green tea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4706407A (en) * 1985-10-04 1987-11-17 Melton Melvin M Animal trap
USPP6627P (en) * 1987-09-21 1989-02-21 The Regents Of The University Of California Avocado tree called Barr Duke
DK0699393T3 (en) * 1994-09-03 1999-08-16 Nestle Sa Process for producing cold water soluble instant black tea
JPH08332061A (en) 1995-06-07 1996-12-17 Sanki Shoji Kk Avocado leaf tea and its beverages and extracts
FR2750606B1 (en) 1996-07-03 1999-01-29 Maurel Sante ORGANOMETALLIC COMPLEXES BASED ON SITOSTEROLS AND DIGLYCERIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6303803B1 (en) 1997-01-31 2001-10-16 Cargill, Incorporated Removal of sterols from fats and oils
US6267963B1 (en) 1999-06-02 2001-07-31 Kraft Foods, Inc. Plant sterol-emulsifier complexes
US6190720B1 (en) 1999-06-15 2001-02-20 Opta Food Ingredients, Inc. Dispersible sterol compositions

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501004A (en) * 2004-05-28 2008-01-17 ラボラトワール エクスパンシアンス Use of furan alkyls to produce drugs for the treatment of obesity and cosmetic treatment of overweight
JP2008501003A (en) * 2004-05-28 2008-01-17 ラボラトワール エクスパンシアンス Use of furanalkyl to manufacture antidiabetic drugs
JP4842260B2 (en) * 2004-05-28 2011-12-21 ラボラトワール エクスパンシアンス Use of furan alkyls to produce drugs for the treatment of obesity and cosmetic treatment of overweight
US8859617B2 (en) 2004-05-28 2014-10-14 Laboratoires Expanscience Use of furan alkyl for preparing an antidiabetic drug
WO2017063150A1 (en) * 2015-10-14 2017-04-20 高雄医学大学 Application of avocado extract, avocadenol b, and (2r,4r)-1,2,4-trihydroxy heptadec-16-yne, and health food comprising avocado extract

Also Published As

Publication number Publication date
WO2004014298A3 (en) 2004-07-01
US6793946B2 (en) 2004-09-21
AU2003257051A1 (en) 2004-02-25
TW200404560A (en) 2004-04-01
KR20050026084A (en) 2005-03-14
JP2005534714A (en) 2005-11-17
US20040022883A1 (en) 2004-02-05
WO2004014298B1 (en) 2004-08-26
CN1681523A (en) 2005-10-12
AU2003257051A8 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
TWI225403B (en) Plant extracts for the treatment of increased bone resorption
Freedman et al. Erythrocytes from magnesium-deficient hamsters display an enhanced susceptibility to oxidative stress
Grases et al. The influence of Zea mays on urinary risk factors for kidney stones in rats
JP2007536250A (en) Nutritional composition for increasing creatine uptake in skeletal muscle
US6793946B2 (en) Composition and method for lowering cholesterol
CN109700011A (en) A kind of health food and preparation method thereof improving sleep
US20050208163A1 (en) Compositions containing avocado leaf extract for lowering cholesterol levels
US20080139657A1 (en) Method for increasing serotonin levels in a person by administration of a composition incorporating (-)hydroxycitric acid, and related compositions thereof
CN105876390A (en) Dried orange peel functional salt with oxidation resistance
El-Shaer et al. Effect of intake of Garcinia cambogia peels on induced-obesity rats
KR101596728B1 (en) Composition comprising zinc/red ginseng, octacosanol and vitamin for preventing and ameliorating andropause symptoms
US20210386813A1 (en) Composition for treating overweight and/or obesity
RU2113855C1 (en) Biologically-active local antiinflammatory and antidegenetarive-dystrophic dough, method of its preparation, species of medicinal plants for it, and method for treatment of inflammatory, denerative-dystrophic diseases of locomotor system
EP1827136A1 (en) Formulation for oral administration having a health-promoting effect on the cardiovascular system
JPH1075750A (en) Garlic-based health beverage
Richard Assessment of calcium carbide and natural ripened pawpaw (Carica papaya) fruits on biochemical parameters of Wistar rats
CN106822684A (en) Prevent and treat Chinese medicine composition, medicine of hyperuricemia and its preparation method and application
JPH03209330A (en) Anti-inflammatory composition
CN104012722B (en) A kind of preserved egg tea and preparation method thereof
CN105685995A (en) Weight-losing composition
CN110302340A (en) A kind of Chinese medicinal tablet and preparation method thereof with hypolipemic function
CN110916039A (en) Nutritional metabolism acid-base balance regulator and preparation method thereof
KR20020030687A (en) Extract Polygonatum and composition caontaining the same with hypocholesterolemic and hypoglycemic activities
CN102488196A (en) Health food using purple sweet potato and sea-buckthorn as main raw materials and preparation method thereof
CN108652007A (en) The health food and preparation method of anti-oxidation function

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20040719

WWE Wipo information: entry into national phase

Ref document number: 1020057001773

Country of ref document: KR

Ref document number: 2004527681

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020057001773

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038220555

Country of ref document: CN

122 Ep: pct application non-entry in european phase